US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NETLease Corporate Real Estate ETF

26.81

+0.20000.75%

Post-market: 26.79-0.0190-0.07%16:00 EDT

Volume:7K

Turnover:199.30K

Market Cap:55.63M

PE:- -

High:26.81

Open:26.81

Low:26.68

Close:26.61

52wk High:28.43

52wk Low:23.56

Shares:2.08M

Float Shares:2.08M

Volume Ratio:0.68

T/O Rate:0.36%

Dividend:1.25

Dividend Rate:4.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Breakthrough: AstraZeneca and Daiichi Sankyo's ADC Shows Strong Efficacy in First-Line Lung Cancer Therapy

Will Realty Income's (O) Convertible Notes And Buyback Shift Its Growth Funding And Dilution Narrative

Simply Wall St.

VICI Properties (VICI) Completes Debt Refinance, Is The Discount To Fair Value Too Wide?

Simply Wall St.

CBRE Group (CBRE) Says US Property Cap Rates Held Steady In H1 2026

Simply Wall St.

VICI Properties Completes $1.75 Billion Senior Notes Offering

MT Newswires Live

VICI Properties Announces Closing of $1.75 Billion Senior Unsecured Notes Offering

THOMSON REUTERS

Realty Income Closes USD 1 Billion Convertible Senior Notes Offering

Realty Income Announces Closing of $1.0 Billion Convertible Senior Notes Offering

THOMSON REUTERS

ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says

MT Newswires Live

Boan Biotechnology Advances First-in-Class CD228 ADC With Positive Early Trial Data

Bioan Biotech's BA1302 (CD228 ADC) Completes China Phase Ia Clinical Study

Innate Pharma launches €22.5m share placement to fund ADC pipeline and extend runway

Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform

Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Agree Realty Declares Monthly Distribution of R$ 0.12 Per Unit, Payable Sept. 21

W. P. Carey is Maintained at Sector Perform by Scotiabank

ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path

Press Release: ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Press Release: Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

New Approval in China for Enhertu, a Key Antibody-Drug Conjugate from Daiichi Sankyo and AstraZeneca

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NETL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NETL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","market":"US","secType":"STK","nameCN":"NETLease Corporate Real Estate ETF","latestPrice":26.81,"timestamp":1787601600000,"preClose":26.61,"halted":0,"volume":7447,"hourTrading":{"tag":"盘后","latestPrice":26.791,"preClose":26.81,"latestTime":"16:00 EDT","volume":2,"amount":53.582,"timestamp":1787601610883,"change":-0.019,"changeRate":-0.000709,"amplitude":0},"delay":0,"changeRate":0.007515971439308504,"floatShares":2075000,"shares":2075000,"eps":0,"marketStatus":"Post-Mkt","change":0.2,"latestTime":"08-24 16:01:31 EDT","open":26.8094,"high":26.81,"low":26.6796,"amount":199297,"amplitude":0.0049,"askPrice":33.35,"askSize":100,"bidPrice":20.93,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":26.61,"sharesOutstanding":1775000,"nav":26.69,"aum":55381750,"dividendRate":0.046651,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.791,"preClose":26.81,"latestTime":"16:00 EDT","volume":2,"amount":53.582,"timestamp":1787601610883,"change":-0.019,"changeRate":-0.000709,"amplitude":0},"volumeRatio":0.683512,"impliedVol":0.0633,"impliedVolPercentile":0.0438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","floatShares":2075000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.683512,"shares":2075000,"dividePrice":1.2507,"high":26.81,"amplitude":0.0049,"preClose":26.61,"low":26.6796,"week52Low":23.56,"pbRate":"--","week52High":28.4299,"institutionHeld":0,"latestPrice":26.81,"eps":0,"divideRate":0.046651,"volume":7447,"delay":0,"ttmEps":0,"open":26.8094,"prevYearClose":23.727,"prevWeekClose":26.61,"prevMonthClose":27.14,"prevQuarterClose":26.7001,"fiveDayClose":26.48,"twentyDayClose":27.9307,"sixtyDayClose":26.3675},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NETL\",params:#limit:5,,,undefined,":[{"date":"2026-07-29","symbol":"NETL","amount":0.105,"announcedDate":"2026-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-29","defaultRemindTime":1785331800000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-29","currency":"USD","dateTimestamp":1785297600000,"payDate":"2026-07-31"},{"date":"2026-06-26","symbol":"NETL","amount":0.105,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-06-30"},{"date":"2026-05-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-05-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-27","defaultRemindTime":1779888600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-27","currency":"USD","dateTimestamp":1779854400000,"payDate":"2026-05-29"},{"date":"2026-04-28","symbol":"NETL","amount":0.105,"announcedDate":"2026-04-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-04-30"},{"date":"2026-03-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-27","defaultRemindTime":1774618200000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-27","currency":"USD","dateTimestamp":1774584000000,"payDate":"2026-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NETL\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":"2020-01-02","value":0.031935,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0097783,"currency":"USD"},{"executeDate":"2020-03-31","recordDate":"2020-04-01","paymentDate":"2020-04-02","value":0.1912399,"currency":"USD"},{"executeDate":"2020-06-26","recordDate":"2020-06-29","paymentDate":"2020-06-30","value":0.2782635,"currency":"USD"},{"executeDate":"2020-09-15","recordDate":"2020-09-16","paymentDate":"2020-09-30","value":0.2792338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NETL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NETL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132478153","title":"Breakthrough: AstraZeneca and Daiichi Sankyo's ADC Shows Strong Efficacy in First-Line Lung Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1132478153","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132478153?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:48","pubTimestamp":1786970902,"startTime":"0","endTime":"0","summary":"On August 17, AstraZeneca PLC and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 trial evaluating Enhertu (trastuzumab deruxtecan) as a monotherapy in the first-line treatment of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU1267930573.SGD","LU2456880835.USD","BK4080","LU0708994859.HKD","IE00B3T34201.USD","LU2237443549.SGD","BK4588","LU2237443895.HKD","LU2237443622.USD","AZN","ADC","LU0058720904.USD","NETL","BK4134","LU2237443978.SGD","LU0310800379.SGD","BK4568","LU0289739699.SGD","LU2237443382.USD","LU2237443465.HKD","LU2468319806.SGD","BK4231","LU1829250122.USD","BK4007","LU0029864427.USD","III","LU2417539215.USD","LU0889565916.HKD","LU2236285917.USD","LU0109394709.USD","LU0320765992.SGD","LU0432979614.USD","LU0128525929.USD","LU2089984988.USD","BK4585","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660107926","title":"Will Realty Income's (O) Convertible Notes And Buyback Shift Its Growth Funding And Dilution Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2660107926","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660107926?lang=en_us&edition=fundamental","pubTime":"2026-08-17 12:40","pubTimestamp":1786941659,"startTime":"0","endTime":"0","summary":"Earlier this month, Realty Income Corporation completed a private offering of US$875 million in 3.750% convertible senior notes due August 15, 2031, issued at 100% of principal, callable and unsecured under Rule 144A. \nThe transaction, paired with plans to use proceeds for a US$750 million-plus share repurchase and balance sheet priorities, highlights how Realty Income is using convertible debt and capped call structures to fund growth while aiming to limit future equity dilution. \nWe’ll now...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/339305-main-header/1756255618638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/339305-main-header/1756255618638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-o/realty-income/news/will-realty-incomes-o-convertible-notes-and-buyback-shift-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-o/realty-income/news/will-realty-incomes-o-convertible-notes-and-buyback-shift-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CLIM","DFAR","SRHR","AIPO","ERET","TSRS","BK4231","DPRE","BK4585","BK4080","BK4588","RWR","NETL","O"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660033281","title":"VICI Properties (VICI) Completes Debt Refinance, Is The Discount To Fair Value Too Wide?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660033281","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660033281?lang=en_us&edition=fundamental","pubTime":"2026-08-17 04:23","pubTimestamp":1786911804,"startTime":"0","endTime":"0","summary":"VICI Properties (VICI) recently completed a public offering of $1.75b in senior unsecured notes, with proceeds earmarked to repay part of its senior notes maturing in 2026 and drawing investor attention to the stock.\nSee our latest analysis for VICI Properties.\nAt a share price of $26.36, VICI Properties has seen its share price drift lower in recent months, with a 30 day share price return of 1.90% down and a 1 year total shareholder return of 13.64% down, which suggests recent refinancing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551737-choice2-main-header/1585186740457","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551737-choice2-main-header/1585186740457"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-vici/vici-properties/news/vici-properties-vici-completes-debt-refinance-is-the-discoun","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-vici/vici-properties/news/vici-properties-vici-completes-debt-refinance-is-the-discoun","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4234","GQRE","DDM","BK4084","DXD","SDOW","DOG","BK4588","DIA","TSRS","BK4561","BK4585","UDOW","NETL","VICI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659179634","title":"CBRE Group (CBRE) Says US Property Cap Rates Held Steady In H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659179634","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659179634?lang=en_us&edition=fundamental","pubTime":"2026-08-16 05:29","pubTimestamp":1786829381,"startTime":"0","endTime":"0","summary":"CBRE Group (NYSE:CBRE) released its H1 2026 Cap Rate Survey, showing steady headline cap rates across US commercial property despite interest rate volatility.\nThe survey highlights split investor sentiment by asset class and region, with differing expectations for pricing and risk across sectors.\nCBRE reported that Manhattan office rents for high quality space are rising as available prime inventory tightens.\nThe combination of stable cap rates and firming Manhattan office rents points to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9612016-choice1-main-header/1585186652017","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9612016-choice1-main-header/1585186652017"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-cbre/cbre-group/news/cbre-group-cbre-says-us-property-cap-rates-held-steady-in-h1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-cbre/cbre-group/news/cbre-group-cbre-says-us-property-cap-rates-held-steady-in-h1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4079","BK4585","LU0320765489.SGD","LU0154245673.USD","SG9999004253.SGD","LU0648001328.SGD","BK4548","LU0208291251.USD","JRE","LU0980610538.SGD","REIT","LU1201861249.SGD","GABF","RSPF","BK4550","URE","LU1496350171.SGD","INDS","CFA.SI","JPRE","BLDG","RWR","LU0130102774.USD","LU0154245756.USD","LU0209137388.USD","USRT","CLR.SI","SRS","DESK","GLS.SI","PSR","JJJ.SI","SRT.SI","BPRE","RNTY","LU0477156953.USD","SRHR","NETL","LU2463526074.USD","CBRE","LU1496350502.SGD","DFAR","LPRE","CSRE","RWO","SRU.SI","LU1983260115.SGD","DPRE","BK4588","IEFN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659212904","title":"VICI Properties Completes $1.75 Billion Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2659212904","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659212904?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:38","pubTimestamp":1786739903,"startTime":"0","endTime":"0","summary":"VICI Properties  subsidiary VICI Properties LP completed its $1.75 billion public offering of senior unsecured notes.The offering included $900 million of 5.4% notes due 2031, priced at 99.966% of par value, and $850 million of 5.75% notes due 2036, priced at 98.375% of par, VICI Properties said Friday in a statement.Net proceeds will be used to repay outstanding senior notes due 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4084","BK4561","BK4234","TSRS","NETL","VICI","BK4585","GQRE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129362","title":"VICI Properties Announces Closing of $1.75 Billion Senior Unsecured Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129362?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:15","pubTimestamp":1786738500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA7KHSFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TSRS","BK4585","BK4234","BK4588","GQRE","VICI","NETL","BK4084","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126755","title":"Realty Income Closes USD 1 Billion Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126755","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126755?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:06","pubTimestamp":1786737964,"startTime":"0","endTime":"0","summary":"Realty Income closes USD 1 billion convertible senior notes offeringRealty Income closed a USD 1 billion private offering of 3.750% convertible senior notes due 2031.Deal size reflects the USD 875 mil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL91kdBy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NETL","RWR","DFAR","BK4231","ERET","TSRS","DPRE","BK4080","SRHR","O","CLIM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659012622","title":"Realty Income Announces Closing of $1.0 Billion Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2659012622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659012622?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA1V1WX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4080","DFAR","RWR","BK4585","TSRS","BK4231","DPRE","BK4588","ERET","NETL","SRHR","O","CLIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659914054","title":"ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659914054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659914054?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:46","pubTimestamp":1786718801,"startTime":"0","endTime":"0","summary":"ADC Therapeutics (ADCT) faces a tougher regulatory path for LOTIS-5, but strong LOTIS-7 data could create meaningful upside, RBC Capital Markets said in a note emailed Friday.The analysts said they se","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4505","BK4080","ADC","NETL","LENZ","ADCT","BK4231","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659514036","title":"Boan Biotechnology Advances First-in-Class CD228 ADC With Positive Early Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2659514036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659514036?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:38","pubTimestamp":1786718334,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Company., Limited. Class H ( ($HK:6955) ) has provided an announcement. Shandong Boan Biotechnology has reported comple...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/boan-biotechnology-advances-first-in-class-cd228-adc-with-positive-early-trial-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/boan-biotechnology-advances-first-in-class-cd228-adc-with-positive-early-trial-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","NETL","BK4231","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196352387","title":"Bioan Biotech's BA1302 (CD228 ADC) Completes China Phase Ia Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1196352387","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196352387?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:26","pubTimestamp":1786717576,"startTime":"0","endTime":"0","summary":"BOAN BIOTECH (06955) has announced that its independently developed innovative antibody-drug conjugate (ADC) targeting CD228, BA1302, has completed the monotherapy dose-escalation phase (Phase Ia) of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK4231","NETL","BK4080","ADC","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659160372","title":"Innate Pharma launches €22.5m share placement to fund ADC pipeline and extend runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160372","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160372?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:32","pubTimestamp":1786653149,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Innate Pharma SA ( ($FR:IPH) ). Innate Pharma has launched a roughly €22.5 million private placement of new ord...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-launches-e22-5m-share-placement-to-fund-adc-pipeline-and-extend-runway?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-launches-e22-5m-share-placement-to-fund-adc-pipeline-and-extend-runway?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","BK4080","IPHYF","NETL","ADC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659678961","title":"Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2659678961","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659678961?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652100,"startTime":"0","endTime":"0","summary":"million in gross proeeds, and warrant exercises worth $3.1 million in. gross proceeds for a total of approximately $8.6 million in gross. proceeds from financing in the quarter, resulting in approximately $8.0. -- Continued advancing AKTX-101 through IND-enabling activities by. progressing manufacturing and development work to enable the Phase 1. clinical trial. The Company remains focused on initiating AKTX-101 for. -- Expanded the Company's strategic position in novel ADC payloads through a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","AKTX","BK4231","BK4139","BK4007","BK4080","PRGS","NETL","ADC","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659683162","title":"Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659683162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659683162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer , continues enrolling with interim analysis on. -- Phase 3 protocol of roxadustat for the treatment of anemia in patients. burden  has been finalized with the goal to initiate the. -- Additional data from the Phase 3 MATTERHORN study were presented at the. improvements in transfusion independence in patients with HTB and. -- Cash, cash equivalents, investments, and accounts receivable of $95.7. -- Kyntra Bio to host conference call and webcast presentation today at 5:00. first-in-class ADC targeting CD46 in mCRPC continues; interim analysis is. on track for the fourth quarter of 2026.Roxadustat-- Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia. in patients with LR-MDS and high transfusion burden  has been. -- In a post hoc analysis of the Phase 3 MATTERHORN study, patients. treated with roxadustat showed a clinically meaningful improvement. in transfusion independence ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HTB","BK4022","LU2236285917.USD","TM","BK4211","BK4099","BK4080","BK4231","03160","BK4206","BK4588","NETL","LU0052756011.USD","KYNB","LU0128525689.USD","LU0211328371.USD","LU0310799852.SGD","DD","ADC","BK4232","BK4604","LU1267930227.SGD","BK4139","LU0211327993.USD","R","BK4555","BK4109","LU0310800965.SGD","LU1267930490.SGD","BK4585","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659693751","title":"Agree Realty Declares Monthly Distribution of R$ 0.12 Per Unit, Payable Sept. 21","url":"https://stock-news.laohu8.com/highlight/detail?id=2659693751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659693751?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:01","pubTimestamp":1786640472,"startTime":"0","endTime":"0","summary":"Agree Realty declares monthly distribution of R$ 0.12 per unit, payable Sept. 21Agree Realty declared a monthly distribution for fiscal 2026 of R$ 0.12 per unit (ISIN BRA1DCBDR003).Holders on record a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLpLtK7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","NETL","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166814","title":"W. P. Carey is Maintained at Sector Perform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166814?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:49","pubTimestamp":1786636140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WPC/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","WPC","INDS","BK4160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659688191","title":"ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2659688191","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659688191?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:49","pubTimestamp":1786628981,"startTime":"0","endTime":"0","summary":"ADC Therapeutics ( ($ADCT) ) has issued an update. On August 13, 2026, ADC Therapeutics reported second-quarter 2026 results, with net product reve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adc-therapeutics-reports-q2-2026-results-reassesses-zynlonta-path?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adc-therapeutics-reports-q2-2026-results-reassesses-zynlonta-path?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","ADC","LENZ","BK4231","BK4539","BK4007","BK4139","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159750","title":"Press Release: ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159750","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159750?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620600,"startTime":"0","endTime":"0","summary":"Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASHCompany eval","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4588","BK4231","LU2463526074.USD","BK4139","BK4109","ASH","BK4022","BK4211","ADC","LENZ","PFS","BK4585","BK4539","BK4080","LABU","NETL","BK4232","BK4007","BK4505","BK4195","ADCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156389","title":"Press Release: Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156389?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618800,"startTime":"0","endTime":"0","summary":"Phase 1 monotherapy study for 2L+ R/M HNSCC in Fall 2026. The update is. expected to include patients treated at 5.4 mg/kg IV Q3W with a dose. equivalent to or below a dose cap, together with detailed analyses of the. dose cap impact on safety, tolerability, efficacy and initial durability.-- The Company completed target enrollment in the Phase 1 Part 2. monotherapy dose expansion study in the first quarter of 2026.-- The ongoing MICVO Phase 1 monotherapy study is a multi-part study.Part 1 was a dose escalation study across multiple doses and tumor. types, with initial results shared in November 2024. Part 2, a. dose expansion study in 2L+ R/M HNSCC, is currently ongoing.Preliminary Phase 1 study results in 2L+ R/M HNSCC were shared in. December 2025, supporting MICVO's broad potential to address a. significant unmet need for patients regardless of HPV status or","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PYXS","R","BK4080","BK4107","LU0210528500.USD","LU2487616109.SGD","BK4232","BK4022","BK4231","NETL","BK4139","L","ADC","LU0053666078.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121610795","title":"New Approval in China for Enhertu, a Key Antibody-Drug Conjugate from Daiichi Sankyo and AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=1121610795","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121610795?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:28","pubTimestamp":1786577294,"startTime":"0","endTime":"0","summary":"A new indication for the antibody-drug conjugate (ADC) Enhertu, developed in collaboration between Daiichi Sankyo and AstraZeneca PLC (AZN.US), has secured approval for marketing in China as of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","LU2468319806.SGD","LU2089984988.USD","LU2456880835.USD","BK4231","BK4007","LU0029864427.USD","LU2236285917.USD","BK4588","IPOS","LU2237443622.USD","LU0289739699.SGD","IE00B3T34201.USD","LU0109394709.USD","LU0128525929.USD","LU2237443549.SGD","NETL","BK4585","LU0708994859.HKD","ADC","BK4568","LU0058720904.USD","BK4080","LU2237443382.USD","AZNH","LU1829250122.USD","LU2237443895.HKD","LU0310800379.SGD","LU2237443465.HKD","LU0320765992.SGD","LU1267930573.SGD","LU0432979614.USD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}